VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LFCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LFCRLifecore Biomedical, Inc.
$5.17$194M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksLFCRCash Flow

Lifecore Biomedical, Inc. (LFCR) Cash Flow Statement

29Y historyFree accessUpdated daily

Earnings quality remains poor, as evidenced by a negative OCF/NI ratio of -0.31 in 2026Q3, indicating that accounting losses are not being offset by core operational cash generation.

LFCR Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMay'25May'24May'23May'22May'21May'20May'19May'18May'17May'16May'15May'14May'13May'12May'11May'10May'09May'08May'07May'06May'05May'04Oct'02Oct'01Oct'00Oct'99Oct'98Oct'97Oct'96
Cash from Operations17.38M-206K257K-17.44M-22.59M16.47M-17.04M16.02M19.78M29.33M21.78M26.16M21.05M21.23M22.18M14.47M7.48M9.44M17.52M-2.06M10.87M13.05M7.93M-101K-7.57M5.01M-3.6M-3.4M-5.5M-3.6M
Operating CF Margin %--0.16%0.2%-16.89%-20.3%16.33%-10.65%2.87%3.77%5.51%4.03%4.85%4.41%4.81%6.98%5.23%3.14%4%7.35%-0.98%4.68%6.36%4.13%-0.06%-3.97%2.39%-10.17%-10.15%-57.89%-144%
Operating CF Growth %818.71%-180.16%101.47%22.8%-237.17%196.66%-206.37%-19%-32.56%34.63%-16.71%24.28%-0.87%-4.29%53.3%93.36%-20.69%-46.15%949.66%-118.98%-16.73%64.48%7954.46%98.67%-251.14%239.11%-5.88%38.18%-52.78%-
Net Income-34.09M-38.72M12.01M-99.56M-116.72M-32.29M-15.15M411K24.92M10.68M-11.45M13.72M19.34M22.81M13.1M4.26M3.98M7.73M13.54M29.19M8.65M5.4M2.9M-1.49M-4.84M-2.08M-2.8M-2.9M-8.6M-4.2M
Depreciation & Amortization9.76M8.03M7.95M13.18M18.06M19.87M18.84M15.23M12.41M10.68M9.39M7.09M7.11M7.29M5.62M5.31M3.36M3.14M3.2M3.26M3.2M3.47M3.71M3.5M5.43M6.07M2.2M2.1M1.1M500K
Stock-Based Compensation4.21M10.16M6.2M3.61M2.61M3.36M2.38K3.56M4.4M3.96M3.46M1.58M1.36M1.7M1.87M1.95M1.02M933K000000000000
Deferred Taxes33K0163K357K-6.83M-7.87M-5.44M910K-7.22M2.51M-9.94M3.69M3.68M5.21M-774K2.49M3.25M2.57M-611K00000000000
Other Non-Cash Items36.11M25.02M-22.38M45.19M83.38M23.65M12.37M-2.91M-4.64M919K32.85M-3.2M-9.67M-11.82M-5.83M3.34M165K-2.14M548K-24M-902K563K609K2.17M-2.49M1.1M0-200K3M100K
Working Capital Changes1.35M-4.7M-3.7M19.79M-3.1M9.76M-27.66M-1.18M-10.1M584K-2.54M3.27M-779K-3.96M8.19M-2.89M-4.29M-2.79M837K-10.51M-87K3.62M719K-4.29M-5.67M-76K-3M-2.4M-1M-100K
Change in Receivables8.6M-2.26M-2.39M10.82M-6.14M5.78M-6.64M-8.86M-7.31M-336K73K-1.75M-7.98M-4.47M-3.12M-5.81M-1.66M4.18M000000000000
Change in Inventory6.44M7.69M862K-14.81M-2.18M-2.82M-12.18M-10.93M-6.53M855K-508K-292K-622K-2.1M-441K-4.05M-1.27M1.5M-529K-8.73M-3.12M1.31M250K4.52M-1.86M-2.39M-3M-2M0-100K
Change in Payables734K-1.67M-6.68M16.04M9.34M-5.98M-1.25M19.12M4.96M-5.19M-4.11M2.89M-141K8.84M-68K2.34M1.01M-5.93M000000000000
Cash from Investing3.09M-6.42M-18.39M-4.81M79.96M-12.31M-23.89M-96.8M-35.59M-25.01M-41.59M-34.44M-13.34M-10.42M-44.07M-29.39M-42.8M-12.34M-20.21M42.04M-5.49M-5.2M-1.37M7.52M-4M-15.62M-3.1M4.1M5.7M-20.7M
Capital Expenditures-6.91M-13.41M-18.39M-21.48M-29.94M-25.22M-26.69M-44.73M-33.59M-22.59M-40.87M-17.51M-14.89M-8.88M-5.37M-6.68M-44.87M-4.58M-4.24M-6.78M-4.75M-3.66M-3.39M-2.55M-6.96M-5.34M-4.1M-4.5M-1.3M-400K
CapEx % of Revenue5.11%10.41%14.34%20.8%26.91%25%16.67%8.02%6.41%4.24%7.55%3.25%3.12%2.01%1.69%2.42%18.84%1.94%1.78%3.22%2.05%1.78%1.77%1.39%3.65%2.55%11.58%13.43%13.68%16%
Acquisitions10M7M016.67M73.5M02.43M-59.87M-4.11M-2.5M-121K000-66.83M00-7K-1.43M-1.22M-3.86M00-491K-257K-6.79M0000
Investments------------------------------
Other Investing0000-8.7M12.91M364K545K-2M81K-723K1.07M1.54M-1.54M00-39.68M101K104K50.04M1.15M430K2.02M10.55M3.22M-3.49M0100K-5.8M0
Cash from Financing-5.09M6.42M7.51M39.7M-57.02M-3.42M40.02M79.03M13.29M-8.8M15.57M8.17M-7.18M-19.27M35.93M-4.76M19.67M1.97M-15.47M2.06M2.27M-1.44M-3.8M-8.26M11.62M17M700K3.3M-9.2M34.9M
Debt Issued (Net)-5.13M-18.56M2.17M3.12M-55.41M7.47M41.77M54.91M18.92M-8.63M15.6M8.15M-9.93M-14.68M39.15M-3.94M19.61M007.35M-1.14M-5.91M-4.5M-15.87M6.32M6.57M290K-6.7M-600K-200K
Equity Issued (Net)-8K23.85M042.9M0030K327K56K706K322K122K2.3M3.42M-4.95M-1.06M379K379K-18.38M-4.66M3.48M5.16M849K7.61M5.54M9.86M468K1.1M200K35.2M
Dividends Paid000000000000000000000000000000
Share Repurchases00000000000000-5.01M-1.18M00-19.5M-7.38M0000000000
Other Financing51K1.13M5.34M-6.32M-1.61M-10.89M-1.79M23.79M-5.69M-874K-495K-563K456K-8.01M1.73M234K-320K1.59M2.91M-630K-75K-690K-438K0-229K-138K08.9M-8.8M-100K
Net Change in Cash3.42M-197K-10.63M17.45M348K742K-912K-1.75M-2.52M-4.49M-4.23M-116K525K-8.46M14.04M-19.68M-15.64M-937K-18.16M42.04M7.65M6.41M2.76M-846K59K6.39M-6M4M-9M10.6M
Free Cash Flow10.47M-13.62M-18.14M-38.92M-52.53M-8.75M-43.73M-28.71M-13.81M6.74M-19.08M8.64M6.16M12.35M16.81M7.79M-37.39M4.86M13.28M-8.84M6.12M9.39M4.54M-2.65M-14.53M-330K-7.7M-7.9M-6.8M-4M
FCF Margin %7.74%-10.57%-14.14%-37.69%-47.21%-8.68%-27.32%-5.15%-2.63%1.27%-3.53%1.6%1.29%2.8%5.29%2.81%-15.7%2.06%5.57%-4.2%2.64%4.58%2.36%-1.45%-7.61%-0.16%-21.75%-23.58%-71.58%-160%
FCF Growth %196.3%24.9%53.4%25.91%-500.24%79.98%-52.28%-107.91%-305.06%135.29%-320.77%40.35%-50.14%-26.51%115.93%120.82%-869.52%-63.41%250.16%-244.53%-34.83%106.83%271.51%81.78%-4303.03%95.71%2.53%-16.18%-70%-
FCF per Share0.28-0.39-0.49-1.30-1.78-0.30-1.50-1.00-0.490.24-0.700.320.230.460.640.29-1.400.180.49-0.330.240.380.19-0.15-0.89-0.02-0.77-0.59-0.61-0.51
FCF Conversion (FCF/Net Income)-0.31x0.01x0.02x0.18x0.19x-0.51x0.45x7.55x0.80x2.77x-1.87x1.93x1.10x0.94x1.75x3.69x1.88x1.22x1.29x-0.07x1.26x2.42x2.74x0.07x0.40x-1.25x1.29x1.17x0.64x0.86x
Interest Paid265K1.91M2.73M31.02M16.89M13.22M002.29M2.33M2.02M1.99M1.5M1.73M-952K761K88K8K000000000000
Taxes Paid17K46K72K23K441K000283K2.79M2.63M150K50K5.61M-246K146K652K1.14M000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and operational insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Quality Remains Severely Disconnected

As evidenced by the persistent divergence between net income and operating cash flow, LFCR's earnings quality is poor, with the company reporting a negative OCF/NI ratio of -0.31 in 2026Q3, indicating that accounting losses are not being offset by meaningful cash generation from core operations.

The consistent inability to align net income with operating cash flow suggests that the company's reported losses are exacerbated by non-cash charges or working capital inefficiencies. Investors should monitor whether this disconnect reflects structural operational challenges or merely the timing of milestone-based revenue recognition within the CDMO segment.

Free Cash Flow Volatility Persists

Based on the provided financial data, LFCR's free cash flow trajectory remains highly erratic, swinging from a peak of $6.0M in 2024Q4 to a low of -$8.6M in 2025Q2, underscoring the difficulty in achieving sustainable cash flow generation amidst ongoing strategic restructuring and operational instability.

The lack of a consistent positive FCF trend suggests that the business is currently unable to self-fund its capital-intensive requirements. This volatility implies that the company remains reliant on external financing or asset divestitures to bridge the gap between its high fixed-cost base and inconsistent revenue streams.

Capital Intensity Pressures Liquidity Profile

According to historical quarterly figures, LFCR maintains a significant capital intensity, with CapEx/Revenue ratios peaking as high as 17.8% in 2024Q3, which places substantial strain on the company's limited cash reserves and complicates its ability to achieve a self-sustaining financial position in the near term.

The high level of capital expenditure relative to revenue suggests that the company is forced to prioritize maintenance and facility upgrades despite its negative operating margins. This capital-intensive nature may limit management's flexibility to pivot toward growth without further dilutive capital raises or debt restructuring.

Working Capital Swings Obscure Performance

As reported in recent financial statements, working capital fluctuations have been a primary driver of cash flow volatility, with a notable $5.5M inflow in 2026Q3 contrasting sharply with an $8.7M outflow in 2025Q2, highlighting the unpredictable nature of the company's cash conversion cycle.

These erratic working capital movements suggest that the company may be struggling with inventory management or the timing of collections from its pharmaceutical partners. Such instability makes it difficult for analysts to forecast normalized cash flow, as the underlying operational efficiency remains masked by these periodic balance sheet adjustments.

LFCR — Frequently Asked Questions

Quick answers to the most common questions about buying LFCR stock.

How much cash does Lifecore Biomedical, Inc. (LFCR) generate from operations?

Lifecore Biomedical, Inc. (LFCR) generated $-0.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Lifecore Biomedical, Inc.'s free cash flow?

Lifecore Biomedical, Inc. (LFCR) reported negative free cash flow of $13.6M in 2025, indicating capital requirements exceeded cash from operations.

What is Lifecore Biomedical, Inc.'s capital expenditure (CapEx)?

Lifecore Biomedical, Inc. (LFCR) spent $13.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.